3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Urinary Bladder, Neurogenic
1
Urinary Bladder Neoplasms
1
Urinary Bladder Diseases
1
Small Cell Lung Carcinoma
1
Neoplasms
1
Malnutrition
1
Gastrointestinal Neoplasms
1
Esophagitis
1
Endometriosis
1
Cystitis, Interstitial
1
Cystitis, Hemorrhagic
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma, Hepatocellular
1
Interventions
Fluorouracil
8
Oxaliplatin
7
Surveys and Questionnaires
6
Leucovorin
6
Blood Specimen Collection
6
Specimen Handling
5
Gemcitabine
5
Cetuximab
5
Capecitabine
5
Bevacizumab
5
fludarabine
4
aldesleukin
4
Standard of Care
4
Cyclophosphamide
4
Remote Patient Monitoring
3
Radiosurgery
3
Pafolacianine
3
Nivolumab
3
Irinotecan
3
Endoscopic Mucosal Resection
3
Cisplatin
3
130-nm albumin-bound paclitaxel
3
encorafenib
2
Tomography, X-Ray Computed
2
Sunitinib
2
Referral and Consultation
2
Radiotherapy
2
Practice Guidelines as Topic
2
Pemetrexed
2
Magnetic Resonance Spectroscopy
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Gastrointestinal Neoplasms
×
Immunonutrition Diet
×
1 year
×
Clear all
NCT01023412
2025-12-10
IPOD-3
Société des Produits Nestlé (SPN)
Phase NA
Terminated
107 enrolled